Atticus Wealth Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Atticus Wealth Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-7	Closed	-$2.3K	–	518
2024 Q4	$2.3K	Hold	7	–	–	﹤0.01%	462
2024 Q3	$2.34K	Hold	7	–	–	﹤0.01%	461
2024 Q2	$1.91K	Hold	7	–	–	﹤0.01%	464
2024 Q1	$2.42K	Hold	7	–	–	﹤0.01%	470
2023 Q4	$2.26K	Hold	7	–	–	﹤0.01%	479
2023 Q3	$2.51K	Hold	7	–	–	﹤0.01%	487
2023 Q2	$2.65K	Hold	7	–	–	﹤0.01%	476
2023 Q1	$3.35K	Buy	7 +2	+40%	+$936	﹤0.01%	451
2022 Q4	$2.1K	Sell	5 -7	-58%	-$2.83K	﹤0.01%	461
2022 Q3	$6K	Hold	12	–	–	﹤0.01%	417
2022 Q2	$6K	Sell	12 -93	-89%	-$48.4K	﹤0.01%	448
2022 Q1	$59K	Sell	105 -17	-14%	-$10.2K	0.02%	231
2021 Q4	$92K	Sell	122 -112	-48%	-$83.8K	0.04%	177
2021 Q3	$175K	Buy	234 +95	+68%	+$71.2K	0.08%	110
2021 Q2	$90K	Buy	139 +14	+11%	+$8.52K	0.04%	180
2021 Q1	$71K	Buy	125 +86	+221%	+$50.9K	0.03%	179
2020 Q4	$23K	Buy	39 +37	+1,850%	+$21.1K	0.01%	252
2020 Q3	$1K	Buy	+2	New	+$1.01K	﹤0.01%	296

Other funds holding BIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Atticus Wealth Management's BIO Position: Q1 2025 in Review

Atticus Wealth Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2025, closing a stake of 7 shares — an estimated $2.3K sold.

Atticus Wealth Management first reported a position in BIO in Q3 2020 and held it in 18 quarters. The position peaked at $175K in Q3 2021. 436 funds tracked by Wall St. Rank hold BIO as of Q1 2025.

Atticus Wealth Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2025 after selling out during the quarter.
Atticus Wealth Management sold 7 Bio-Rad Laboratories Class A shares in Q1 2025, an estimated $2.3K.
Atticus Wealth Management first reported a position in Bio-Rad Laboratories Class A in Q3 2020 and held it in 18 quarters.
Atticus Wealth Management's Bio-Rad Laboratories Class A position peaked at $175K in Q3 2021.
436 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2025.

Based on Atticus Wealth Management's 13F filing for Q1 2025, filed 22 Apr 2025.